Literature DB >> 21355765

Obtaining regulatory approval for multicentre randomised controlled trials: experiences in the STICH II trial.

Gillian M Kenyon1, Alexander David Mendelow, Barbara A Gregson, Elise Rowan.   

Abstract

BACKGROUND AND
PURPOSE: Centres wishing to participate in international multicentre randomised controlled surgical trials such as STICH II (Surgical Trial in Lobar Intracerebral Haemorrhage) have to go through a number of regulatory hurdles. These depend on the nature of the study. In surgical studies, there is a need to obtain ethical approval and individual hospital approval including fully executing contracts between the host organisation and each institution. Firsthand experience has been gained in STICH II by guiding over 80 hospitals through this process in over 20 different countries worldwide.
METHODS: This article examines the administrative challenges of setting up the STICH II trial which include the time that it has taken for each hospital to obtain ethical approval, sign the study agreement and become a fully registered site. The aim of this article is to inform potential triallists planning multinational surgical trials about the potential delays and difficulties that may be encountered in the hope that it will encourage the medical research community to simplify administrative systems. We also hope to influence trial funders to build in 'start up periods' for new studies so that they can get up and running in a realistic time frame. The difficulties which were faced will be highlighted so that the organisers of other randomised controlled surgical trials can be aware of these delays.
CONCLUSION: From the experiences in this trial, it can be concluded that delays will be experienced in obtaining ethical approval and in agreeing on site contracts.

Entities:  

Mesh:

Year:  2011        PMID: 21355765     DOI: 10.3109/02688697.2010.551675

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  5 in total

1.  Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation.

Authors:  Benjamin Speich; Nadine Schur; Dmitry Gryaznov; Belinda von Niederhäusern; Lars G Hemkens; Stefan Schandelmaier; Alain Amstutz; Benjamin Kasenda; Christiane Pauli-Magnus; Elena Ojeda-Ruiz; Yuki Tomonaga; Kimberly McCord; Alain Nordmann; Erik von Elm; Matthias Briel; Matthias Schwenkglenks
Journal:  PLoS One       Date:  2019-01-11       Impact factor: 3.240

2.  Recruitment patterns in a large international randomized controlled trial of perioperative care in cancer patients.

Authors:  Aaron Gazendam; Anthony Bozzo; Patricia Schneider; Victoria Giglio; David Wilson; Michelle Ghert
Journal:  Trials       Date:  2021-03-20       Impact factor: 2.279

3.  Current methods and challenges for acute pain clinical trials.

Authors:  Ian Gilron; Daniel B Carr; Paul J Desjardins; Henrik Kehlet
Journal:  Pain Rep       Date:  2018-04-02

4.  Time required to initiate outbreak and pandemic observational research.

Authors:  Asgar H Rishu; Nicole Marinoff; Lisa Julien; Mariana Dumitrascu; Nicole Marten; Shauna Eggertson; Su Willems; Stacy Ruddell; Dan Lane; Bruce Light; Henry T Stelfox; Philippe Jouvet; Richard Hall; Steven Reynolds; Nick Daneman; Robert A Fowler
Journal:  J Crit Care       Date:  2017-03-01       Impact factor: 3.425

5.  Drivers of Start-Up Delays in Global Randomized Clinical Trials.

Authors:  Jennifer Lai; Leila Forney; Daniel L Brinton; Kit N Simpson
Journal:  Ther Innov Regul Sci       Date:  2020-09-21       Impact factor: 1.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.